Version 2 du 22 septembre 2020
COVID-19 in Africa: What else ?
Philippe Parola, Souleymane Brah, Abdoulaye Djimde, Nadjet Mouffok, Majida Zahraoui, Ali Ould Mohamed Salem Boukhary, Idir Bitam, Mahamadou Ali Thera, Jean-Bernard Lekana-Douki, Eric Adehossi, Moussa Seydi, Jean-Christophe Lagier, Jean Akiana, Jaafar Heikel, Didier Raoult, Cheikh Sokhna
In September 10th, 2020, Margolin et al. reviewed in Nature Reviews Microbiology, the prospects for SARS-Cov-2 in Africa. A couple of weeks before,the factors which may explain the dampened course of COVID-19 in Africa had been discussed in Science (7 August 2020, p 624-626).
We, being Professors of Infectious diseases or microbiology, MD, PhD, coauthors from Algeria, Morocco, Senegal, Niger, Mali, Mauritania, Gabon,Republique du Congo and France, all involved in the COVID 19 pandemic in Africa were stunned that both journals missed or misestimated a major issue about COVID-19 treatment in Africa.
We would like to discuss in this correspondence the potential role of the large use of chloroquine derivative with or without azithromycin in many African countries, including ours.